drugset / Trial / NCT06169995

A Study of Remimazolam Tosilate for Sedation in the Upper Gastrointestinal Endoscopy

NCT06169995

Phase 4 Completed 31 enrolled Jiangsu HengRui Medicine Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of Remimazolam Tosilate for Injection for sedation in Upper Gastrointestinal Endoscopy

Timeline

Start
2023-12-11
Primary completion
2023-12-15
Completion
2023-12-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Remimazolam Small molecule 2.5 mg Intravenous

Indications

No indication recorded.